Mannucci P M, Gringeri A
Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Università degli Studi ed Ospedale Maggiore, Milano.
Ric Clin Lab. 1991 Jan-Mar;21(1):1-7. doi: 10.1007/BF02919111.
Recombinant factor VIII is currently in the late stages of clinical trials. The available studies indicate that the product is safe and well-tolerated, and appears to be free of virus diseases such as HIV and hepatitis infections. Based on these early studies, recombinant coagulation factors appear to have enormous promise and potential for transfusion medicine. The synthesis of large quantities of safe material may lead to the development of techniques for daily administration of factor VIII aimed at the prevention of joint and soft tissue bleedings. There is also the promise of decreased costs, as techniques for the efficient synthesis of recombinant proteins are refined further.
重组凝血因子VIII目前正处于临床试验后期。现有研究表明，该产品安全且耐受性良好，似乎没有诸如艾滋病毒和肝炎感染等病毒疾病。基于这些早期研究，重组凝血因子在输血医学方面似乎具有巨大的前景和潜力。大量安全材料的合成可能会促使开发旨在预防关节和软组织出血的每日注射VIII因子的技术。随着重组蛋白高效合成技术的进一步完善，成本降低也有望实现。
